Brokerages Anticipate OvaScience Inc. (OVAS) Will Announce Quarterly Sales of $100,000.00
Equities research analysts expect OvaScience Inc. (NASDAQ:OVAS) to report sales of $100,000.00 for the current quarter, Zacks reports. Two analysts have made estimates for OvaScience’s earnings. The lowest sales estimate is $90,000.00 and the highest is $100,000.00. OvaScience reported sales of $200,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The business is expected to issue its next earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that OvaScience will report full-year sales of $100,000.00 for the current year, with estimates ranging from $300,000.00 to $330,000.00. For the next fiscal year, analysts forecast that the company will report sales of $2.95 million per share, with estimates ranging from $300,000.00 to $5.59 million. Zacks’ sales averages are an average based on a survey of analysts that follow OvaScience.
OvaScience (NASDAQ:OVAS) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.02. OvaScience had a negative return on equity of 69.13% and a negative net margin of 16,132.47%. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the firm earned ($0.62) earnings per share. The business’s revenue for the quarter was down 55.6% on a year-over-year basis.
OVAS has been the subject of several research reports. Zacks Investment Research downgraded OvaScience from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a research report on Thursday, June 22nd.
Several institutional investors have recently modified their holdings of OVAS. UBS Asset Management Americas Inc. acquired a new position in shares of OvaScience during the 1st quarter worth approximately $107,000. Zacks Investment Management acquired a new position in shares of OvaScience during the 2nd quarter worth approximately $140,000. LMR Partners LLP acquired a new position in shares of OvaScience during the 2nd quarter worth approximately $145,000. Susquehanna International Group LLP raised its position in shares of OvaScience by 87.2% during the 2nd quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 52,538 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of OvaScience by 28.8% during the 2nd quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock worth $256,000 after purchasing an additional 36,720 shares during the last quarter. Hedge funds and other institutional investors own 56.28% of the company’s stock.
OvaScience (NASDAQ:OVAS) remained flat at $1.42 during midday trading on Tuesday. 58,298 shares of the company traded hands. The firm’s market capitalization is $50.67 million. OvaScience has a 1-year low of $1.25 and a 1-year high of $8.98. The stock has a 50-day moving average of $1.45 and a 200-day moving average of $1.48.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.